Valuation: Compass Therapeutics, Inc.

Market Cap 427M 370M 346M 316M 594M 40.71B 603M 4.07B 1.59B 20.38B 1.6B 1.57B 67.97B P/E 2026 *
-4.81x
P/E 2027 * -4.47x
Enterprise Value 277M 240M 225M 205M 385M 26.4B 391M 2.64B 1.03B 13.22B 1.04B 1.02B 44.08B EV / Sales 2026 *
-
EV / Sales 2027 * 12.6x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+7.73%
1 week+25.40%
Current month+24.08%
1 month+1.72%
3 months+26.74%
6 months-62.62%
Current year-55.87%
1 week 2.03
Extreme 2.03
2.38
1 month 1.85
Extreme 1.85
2.38
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
2/8/26 A Tax

Chief Executive Officer

36,687 0.0206%
1/9/26 A Tax

Chief Executive Officer

46,777 0.0263%
1/2/26 A Free

Director

90,000 0.0506%
Change 5-day change 1-year change 3-year change Capi.($)
+7.73%+25.40%-25.24%-8.85% 396M
-0.73%+7.82%+73.81%+102.34% 70.51B
+1.60%+1.66%+37.76%+67.36% 54.05B
-0.22%+33.59%+8.43%+489.75% 28.95B
-0.13%+10.78%+48.83%+7.73% 24.05B
-0.06%+0.61%-16.45%-13.26% 23.31B
-1.37%+7.87%+251.71%+464.53% 18.67B
+2.21%+7.66%+47.18%-20.09% 18.37B
+0.09%+4.33%+26.67%+626.03% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.72B
Average +0.79%+10.26%+48.55%+184.97% 26.71B
Weighted average by Cap. +0.13%+9.60%+54.96%+168.45%

Financials

2026 *2027 *
Net sales - 23.35M 20.23M 18.96M 17.29M 32.51M 2.23B 33.01M 223M 87.15M 1.12B 87.68M 85.77M 3.72B
Net income -93.55M -81.05M -75.94M -69.27M -130M -8.92B -132M -893M -349M -4.47B -351M -344M -14.9B -105M -91.32M -85.56M -78.04M -147M -10.05B -149M -1.01B -393M -5.03B -396M -387M -16.78B
Net Debt -150M -130M -122M -111M -209M -14.31B -212M -1.43B -560M -7.16B -563M -551M -23.89B -133M -115M -108M -98.48M -185M -12.69B -188M -1.27B -496M -6.35B -499M -489M -21.18B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
12/08/26 $2.370 +7.73% 8,287,451
11/08/26 $2.200 -0.90% 3,984,649
10/08/26 $2.220 +3.26% 4,205,751
07/08/26 $2.150 +8.04% 3,827,246
06/08/26 $1.990 +5.29% 6,688,585
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.370USD
Average target price
8.917USD
Spread / Average Target
+276.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock